Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment

N/ARecruitingNCT07197801

Geisinger Clinic218 enrolled

Overview

The goal of this clinical trial is to learn if receiving peer recovery support (support services provided by trained "peers" with lived experience of addiction and recovery) improves retention in medication treatment among people with opioid use disorder. The main question it aims to answer is: does peer recovery support improve retention in medication treatment for opioid use disorder? Researchers will compare two groups: (1) standard care combined with a peer recovery support program, and (2) standard care alone, to see if peer recovery support works to improve retention in medication treatment for opioid use disorder. Participants will: visit clinics as they normally would to receive standard care (medication treatment for opioid use disorder); complete two questionnaires - one when they start treatment and one 6 months later; and agree to let researchers use information from their medical record. Participants in group 1 will also be invited to meet with a peer recovery support specialist for up to 6 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Enrollment

218

Conditions

Opioid Use Disorder

Interventions

The intervention adds a peer recovery support (PRS) program to standard outpatient medication for opioid use disorder treatment and medical care. The PRS program will entail meeting one-on-one with a peer recovery specialist over a 6-month period, who will utilize their lived experience with substance use and recovery to provide emotional, informational, instrumental, and aﬃliational support to participants.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult ≥ 18 years of age * Initiated medication for opioid use disorder treatment in past 45 days in a Geisinger outpatient clinic * Willing and able to give informed consent Exclusion Criteria: * Received medication for opioid use disorder treatment at a Geisinger outpatient clinic in the 90-day period prior to the treatment initiation date * Not proficient in English

Outcomes

Primary Outcomes

6-month treatment retention

Data will come from the electronic health records. Retention will be defined as a participant not having a lapse in days' supply of medication for opioid use disorder treatment (buprenorphine, buprenorphine-naloxone, or naltrexone) within the 6-month follow-up period that is greater than 30 days.

Time frame: 180 days from initiation of medication treatment for opioid use disorder

Length of time in treatment

Data will come from the electronic health records. Length of time in treatment will be determined by summing days' supply of consecutive orders for medications for opioid use disorder treatment(buprenorphine, buprenorphine- naloxone, or naltrexone). Treatment will be considered ended if a participant has a gap in supply of more than 30 days.